Dark

Check out our Level2View

RAPP
Rapport Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Jun 5, 2026 3:59:57 PM EDT

36.06USD-3.801%(-1.43)180,675

29.04Bid 43.93Ask 14.89Spread

Pre-market

0.00USD-100.000%(-37.49)0

After-hours

Jun 5, 2026 4:00:30 PM EDT

36.10USD+0.097%(+0.04)54,342

OverviewOptionsHistoricalExchangesShortsTrends

RAPP Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

RAPP Specific Mentions

As of Jun 5, 2026 4:52:43 PM EDT (58 minutes ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

88 days ago • u/AlbertiApop2029 • r/smallstreetbets • binary_event_phase_iii_data_release_xene_xenon • C

I was so risk adverse going into today, I should have yolo'd. Oh well, looks good going forward as well!
>William Blair analyst Myles Minter [described the results as "unprecedented."](https://www.investors.com/news/technology/xenon-pharmaceuticals-focal-onset-seizures-treatment/)
>"This blows away our bull case expectations of (greater than or equal to) 30% placebo-normalized improvement described in our data preview," he said in a report. "Investors were debating if the bar should be 25% or 30% on a placebo-normalized basis and the data clearly blasts through both."
>Not only does this set Xenon Pharmaceuticals up well to potentially compete with Praxis Precision Medicines (PRAX) and Rapport Therapeutics (RAPP), it could also set Xenon on the path to an acquisition, analysts said.
>Johnson & Johnson (JNJ) spent $14.6 billion to buy neuroscience-focused Intra-Cellular Therapies in 2025. Jazz Pharmaceuticals (JAZZ) bought GW Pharma and its seizure drug for $7.2 billion in 2021.
>**In premarket trades, Xenon Pharmaceuticals shares catapulted more than 43% to 60.10.**

88 days ago • u/AlbertiApop2029 • r/smallstreetbets • binary_event_phase_iii_data_release_xene_xenon • C

I was so risk adverse going into today, I should have yolo'd. Oh well, looks good going forward as well!
>William Blair analyst Myles Minter [described the results as "unprecedented."](https://www.investors.com/news/technology/xenon-pharmaceuticals-focal-onset-seizures-treatment/)
>"This blows away our bull case expectations of (greater than or equal to) 30% placebo-normalized improvement described in our data preview," he said in a report. "Investors were debating if the bar should be 25% or 30% on a placebo-normalized basis and the data clearly blasts through both."
>Not only does this set Xenon Pharmaceuticals up well to potentially compete with Praxis Precision Medicines (PRAX) and Rapport Therapeutics (RAPP), it could also set Xenon on the path to an acquisition, analysts said.
>Johnson & Johnson (JNJ) spent $14.6 billion to buy neuroscience-focused Intra-Cellular Therapies in 2025. Jazz Pharmaceuticals (JAZZ) bought GW Pharma and its seizure drug for $7.2 billion in 2021.
>**In premarket trades, Xenon Pharmaceuticals shares catapulted more than 43% to 60.10.**

Share